Press Releases

Press Release: Execution of a share buyback agreement for up to €2 billion

Media Update: AAAAI: new data reinforce Sanofi’s leadership in immunology and scientific innovation for patients

Press Release: Sanofi announces buy back of shares from L’Oréal

Press Release: Sarclisa is the first anti-CD38 treatment in combination with standard-of-care VRd approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Opella reaches study milestone for Cialis

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Press Release: Jean-Paul Kress to join Sanofi's Board of Directors

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Availability of the Q4 2024 Aide-mémoire

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

Press Release: Availability of the profit and loss information of Sanofi excluding Opella

Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria